HUE035931T2 - N-[2,4-bis(1,1-dimetiletil)-5-hidroxipenil]-1,4-dihidro-4-oxokinolin-3-karboxamid gyógyszerészeti készítménye és annak alkalmazása - Google Patents

N-[2,4-bis(1,1-dimetiletil)-5-hidroxipenil]-1,4-dihidro-4-oxokinolin-3-karboxamid gyógyszerészeti készítménye és annak alkalmazása

Info

Publication number: HUE035931T2
Authority: HU; Hungary
Prior art keywords: hydroxypenyl; oxoquinoline; dimethylethyl; carboxamide; dihydro
Prior art date: 2008-08-13

Application number

HUE09789125A

Other languages

English (en)

Inventor

William Rowe

Patricia Hurter

Christopher Young

Kirk Dinehart

Marinus Verwijs

Kirk Overhoff

Peter Grootenhuis

Martyn Botfield

Alfredo Grossi

Original Assignee

Vertex Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-08-13

Filing date

2009-08-13

Publication date

2018-06-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41206223&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE035931(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-08-13 Application filed by Vertex Pharma filed Critical Vertex Pharma

2018-06-28 Publication of HUE035931T2 publication Critical patent/HUE035931T2/hu

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Physical Education & Sports Medicine (AREA)
Neurosurgery (AREA)
Endocrinology (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)
Obesity (AREA)
Rheumatology (AREA)
Reproductive Health (AREA)
Urology & Nephrology (AREA)
Otolaryngology (AREA)
Hospice & Palliative Care (AREA)
Gastroenterology & Hepatology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Ophthalmology & Optometry (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Psychology (AREA)
Immunology (AREA)
Emergency Medicine (AREA)

HUE09789125A 2008-08-13 2009-08-13 N-[2,4-bis(1,1-dimetiletil)-5-hidroxipenil]-1,4-dihidro-4-oxokinolin-3-karboxamid gyógyszerészeti készítménye és annak alkalmazása HUE035931T2 (hu)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date
US8870408P	2008-08-13	2008-08-13
US8880108P	2008-08-14	2008-08-14
US9009608P	2008-08-19	2008-08-19
US14616309P	2009-01-21	2009-01-21
US18152709P	2009-05-27	2009-05-27
US18334509P	2009-06-02	2009-06-02

Publications (1)

Publication Number	Publication Date
HUE035931T2 true HUE035931T2 (hu)	2018-06-28

Family

ID=41206223

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
HUE17204189A HUE053357T2 (hu)	2008-08-13	2009-08-13	Gyógyszerészeti készítmény és annak beadásai
HUE09789125A HUE035931T2 (hu)	2008-08-13	2009-08-13	N-[2,4-bis(1,1-dimetiletil)-5-hidroxipenil]-1,4-dihidro-4-oxokinolin-3-karboxamid gyógyszerészeti készítménye és annak alkalmazása

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
HUE17204189A HUE053357T2 (hu)	2008-08-13	2009-08-13	Gyógyszerészeti készítmény és annak beadásai

Country Status (28)

Country	Link
US (1)	US20120220625A1 (hu)
EP (3)	EP3842037A1 (hu)
JP (2)	JP5575768B2 (hu)
KR (5)	KR20220057663A (hu)
CN (1)	CN102231990B (hu)
AU (2)	AU2009282419B2 (hu)
BR (1)	BRPI0916877A2 (hu)
CA (1)	CA2733908C (hu)
CY (2)	CY1119945T1 (hu)
DK (2)	DK2328618T3 (hu)
EA (1)	EA021706B1 (hu)
ES (2)	ES2660143T3 (hu)
HK (2)	HK1161140A1 (hu)
HR (2)	HRP20180328T1 (hu)
HU (2)	HUE053357T2 (hu)
IL (3)	IL211203A (hu)
LT (2)	LT2328618T (hu)
ME (1)	ME03019B (hu)
MX (3)	MX373230B (hu)
NO (1)	NO2328618T3 (hu)
NZ (1)	NZ591535A (hu)
PL (2)	PL3345625T3 (hu)
PT (2)	PT3345625T (hu)
RS (2)	RS56894B1 (hu)
SI (2)	SI3345625T1 (hu)
SM (2)	SMT202100077T1 (hu)
WO (1)	WO2010019239A2 (hu)
ZA (1)	ZA201101097B (hu)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20100074949A1 (en)	2008-08-13	2010-03-25	William Rowe	Pharmaceutical composition and administration thereof
AU2004272599A1 (en)	2003-09-06	2005-03-24	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
US7977322B2 (en)	2004-08-20	2011-07-12	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
DK2502911T3 (en)	2004-06-24	2017-06-06	Vertex Pharma	Modulators of ATP-binding cassette transporters
CA2618057A1 (en)	2005-08-11	2007-02-22	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
SI2404919T1 (sl)	2005-11-08	2013-12-31	Vertex Pharmaceuticals Incorporated	Heterocikliäśna spojina uporabna kot modulator za prenaĺ alce z atp-vezavno kaseto
LT1993360T (lt)	2005-12-28	2017-06-12	Vertex Pharmaceuticals Incorporated	N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
CN101395147B (zh)	2005-12-28	2013-05-29	弗特克斯药品有限公司	作为atp-结合盒转运蛋白调节剂用于治疗囊性纤维化的1-(苯并[d][1,3]间二氧杂环戊烯-5-基)-n-(苯基)环丙烷-甲酰胺衍生物及相关化合物
EP2007756B1 (en)	2006-04-07	2015-08-26	Vertex Pharmaceuticals Incorporated	Modulators of atp-binding cassette transporters
US10022352B2 (en)	2006-04-07	2018-07-17	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
US7645789B2 (en)	2006-04-07	2010-01-12	Vertex Pharmaceuticals Incorporated	Indole derivatives as CFTR modulators
US8563573B2 (en)	2007-11-02	2013-10-22	Vertex Pharmaceuticals Incorporated	Azaindole derivatives as CFTR modulators
JP5497633B2 (ja)	2007-05-09	2014-05-21	バーテックスファーマシューティカルズインコーポレイテッド	Ｃｆｔｒのモジュレーター
WO2009038913A2 (en)	2007-08-24	2009-03-26	Vertex Pharmaceuticals Incorporated	Isothiazolopyridinones useful for the treatment of (inter alia) cystic fibrosis
DK2217572T3 (da)	2007-11-16	2014-02-03	Vertex Pharma	Isoquinoliner som modulatorer af ATP-bindingskassettetransportører
ES2993060T3 (en)	2007-12-07	2024-12-20	Vertex Pharma	Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
EP2237768A2 (en) *	2007-12-07	2010-10-13	Vertex Pharmaceuticals Incorporated	Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
PT2231606E (pt)	2007-12-07	2013-05-17	Vertex Pharma	Processos para a produção de ácidos cicloalquilcarboxiamido-piridina benzóicos
US20100036130A1 (en)	2007-12-07	2010-02-11	Vertex Pharmaceuticals Incorporated	Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
CA2716109C (en)	2008-02-28	2016-07-19	Vertex Pharmaceuticals Incorporated	Heteroaryl derivatives as cftr modulators
ES2442945T3 (es)	2008-03-31	2014-02-14	Vertex Pharmaceuticals Inc.	Derivados de piridilo como moduladores del CFTR
AU2009296271A1 (en) *	2008-09-29	2010-04-01	Vertex Pharmaceuticals Incorporated	Dosage units of 3-(6-(1-(2,2-difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
US8513282B2 (en)	2008-10-23	2013-08-20	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
RU2543714C2 (ru)	2009-03-20	2015-03-10	Вертекс Фармасьютикалз Инкорпорейтед	Способ получения модуляторов регулятора трансмембранной проводимости кистозного фиброза
US8802868B2 (en)	2010-03-25	2014-08-12	Vertex Pharmaceuticals Incorporated	Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
HUE056525T2 (hu)	2010-04-07	2022-02-28	Vertex Pharma	3-(6-(1-(2,2-Difluorbenzo[d][1,3]dioxol-5-il)ciklopropánkarboxamido)-3-metilpiridin-2-il)benzoesav gyógyszerészeti készítményei és azok adagolása
DK2555754T3 (en)	2010-04-07	2016-04-18	Vertex Pharma	Solid forms of 3- (6- (1- (2,2-difluoro-benzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido) -3-methylpyridin-2-yl) -benzoic acid
EP3381899B1 (en)	2010-04-22	2021-01-06	Vertex Pharmaceuticals Incorporated	Intermediate compound for process of producing cycloalkylcarboxamido-indole compounds
US8563593B2 (en)	2010-06-08	2013-10-22	Vertex Pharmaceuticals Incorporated	Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
BR112013004130A2 (pt) *	2010-08-27	2016-07-05	Vertex Pharma	composição farmacêutica e administrações da mesma
HUE047354T2 (hu)	2011-05-18	2020-04-28	Vertex Pharmaceuticals Europe Ltd	Ivacaftor deuterizált származékai
ME02749B (me)	2011-05-18	2018-01-20	Concert Pharmaceuticals Inc	Deuterisani derivati ivakaftora
EP2567959B1 (en)	2011-09-12	2014-04-16	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013070961A1 (en)	2011-11-08	2013-05-16	Vertex Pharmaceuticals Incorporated	Modulators of atp-binding cassette transporters
BR112014021090B1 (pt) *	2012-02-27	2023-01-24	Vertex Pharmaceuticals Incorporated	Composição farmacêutica e uso de n-[2,4-bis(1,1-dimetiletil)-5-hidróxifenil]-1,4-di-hidro-4-oxoquinolina3-carboxamida na preparação da mesma
JP6525203B2 (ja) *	2012-04-06	2019-06-05	ザユーエイビーリサーチファウンデーションＴｈｅＵＡＢＲｅｓｅａｒｃｈＦｏｕｎｄａｔｉｏｎ	Ｃｆｔｒ活性を増大させるための方法
EP2872122A1 (en)	2012-07-16	2015-05-20	Vertex Pharmaceuticals Incorporated	Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof
CA2879404A1 (en)	2012-07-20	2014-01-23	Otsuka Pharmaceutical Co., Ltd.	Tablet having dry-ink film on surface thereof, and ink for inkjet printer
SG11201503365YA (en)	2012-11-02	2015-06-29	Vertex Pharma	Pharmaceutical compositions for the treatment of cftr mediated diseases
MY178621A (en)	2012-11-19	2020-10-19	Vertex Pharmaceuticals Europe Ltd	Deuterated cftr potentiators
CA2906008C (en)	2013-03-13	2019-07-09	Flatley Discovery Lab, Llc	Pyridazinone compounds and methods for the treatment of cystic fibrosis
PL3650014T3 (pl) *	2013-08-27	2022-01-31	Gilead Pharmasset Llc	Preparat złożony dwóch związków przeciwwirusowych
SI3068392T1 (sl) *	2013-11-12	2021-07-30	Vertex Pharmaceuticals Incorporated	Postopek za pripravo farmacevtskih sestavkov za zdravljenje bolezni, ki jih posreduje CFTR
SG11201605588YA (en) *	2014-01-09	2016-08-30	Verastem Inc	Compositions and methods for treatment of abnormal cell growth
WO2015138839A1 (en) *	2014-03-14	2015-09-17	Agios Pharmaceuticals, Inc.	Pharmaceutical compositions of therapeutically active compounds
CA2944140C (en)	2014-04-15	2022-10-04	Vertex Pharmaceuticals Incorporated	Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
GB201415381D0 (en)	2014-08-29	2014-10-15	Algipharma As	Inhalable powder formulations of alginate oligomers
PL3203840T3 (pl)	2014-10-06	2021-01-11	Vertex Pharmaceuticals Incorporated	Modulatory mukowiscydozowego przezbłonowego regulatora przewodnictwa
RU2749213C2 (ru) *	2014-10-07	2021-06-07	Вертекс Фармасьютикалз Инкорпорейтед	Сокристаллы модуляторов регулятора трансмембранной проводимости при кистозном фиброзе
ES2882656T3 (es)	2014-11-18	2021-12-02	Vertex Pharma	Proceso para realizar pruebas de alto rendimiento de cromatografía líquida de alta resolución
GB201504878D0 (en)	2015-03-23	2015-05-06	Algipharma As	Use of alginate oligomers and CFTR modulators in the treatment of conditions associated with CFTR dysfuntion
WO2017053455A1 (en)	2015-09-21	2017-03-30	Concert Pharmaceuticals, Inc.	Administration of deuterated cftr potentiators
US10759721B2 (en)	2015-09-25	2020-09-01	Vertex Pharmaceuticals (Europe) Limited	Deuterated CFTR potentiators
GB201517639D0 (en)	2015-10-06	2015-11-18	Algipharma As	Use of alginate oligomers to treat or prevent microbial overgrowth in the intestinal tract
US11337969B2 (en)	2016-04-08	2022-05-24	X4 Pharmaceuticals, Inc.	Methods for treating cancer
FR3055800B1 (fr)	2016-09-15	2020-06-26	Unither Pharmaceuticals	Composition solide a ingestion rapide et deglutition facilitee, sous forme de particules solides non agglomerees, comprenant deux differents types de particules
WO2018064632A1 (en)	2016-09-30	2018-04-05	Vertex Pharmaceuticals Incorporated	Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
EP3812379A1 (en)	2016-12-09	2021-04-28	Vertex Pharmaceuticals Incorporated	Crystalline form of a n-(pyrazol-4-yl)sulfonyl-6-(pyrazol-1-yl)-2-(pyrrolidin-1-yl)pyridine-3-carboxamide for treating cystic fibrosis
AU2018279646B2 (en)	2017-06-08	2023-04-06	Vertex Pharmaceuticals Incorporated	Methods of treatment for cystic fibrosis
CA3068609A1 (en)	2017-07-01	2019-01-10	Vertex Pharmaceuticals Incorporated	Compositions and methods for treatment of cystic fibrosis
CA3069226A1 (en)	2017-07-17	2019-01-24	Vertex Pharmaceuticals Incorporated	Methods of treatment for cystic fibrosis
CA3069225A1 (en)	2017-07-17	2019-01-24	Vertex Pharmaceuticals Incorporated	Methods of treatment for cystic fibrosis
JP7121794B2 (ja)	2017-08-02	2022-08-18	バーテックスファーマシューティカルズインコーポレイテッド	ピロリジン化合物を調製するためのプロセス
TWI719349B (zh)	2017-10-19	2021-02-21	美商維泰克斯製藥公司	Ｃｆｔｒ調節劑之結晶形式及組合物
CN111479804B (zh)	2017-12-01	2023-12-22	弗特克斯药品有限公司	用于制备囊性纤维化跨膜传导调节因子的调节剂的方法
US20210228489A1 (en)	2017-12-04	2021-07-29	Vertex Pharmaceuticals Incorporated	Compositions for treating cystic fibrosis
CA3085006A1 (en)	2017-12-08	2019-06-13	Vertex Pharmaceuticals Incorporated	Processes for making modulators of cystic fibrosis transmembrane conductance regulator
TWI810243B (zh)	2018-02-05	2023-08-01	美商維泰克斯製藥公司	用於治療囊腫纖化症之醫藥組合物
CN117285547A (zh)	2018-02-15	2023-12-26	弗特克斯药品有限公司	作为cftr的调节剂的大环化合物、其药物组合物、它们的用途和制备方法
US20210139514A1 (en)	2018-04-05	2021-05-13	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
EP3774825A1 (en)	2018-04-13	2021-02-17	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
DK3880197T3 (da)	2018-11-14	2023-03-27	Vertex Pharma	Fremgangsmåder til behandling for cystisk fibrose
AR118555A1 (es)	2019-04-03	2021-10-20	Vertex Pharma	Agentes moduladores del regulador de la conductancia transmembrana de la fibrosis quística
WO2020214921A1 (en)	2019-04-17	2020-10-22	Vertex Pharmaceuticals Incorporated	Solid forms of modulators of cftr
WO2020242935A1 (en)	2019-05-29	2020-12-03	Vertex Pharmaceuticals Incorporated	Methods of treatment for cystic fibrosis
TWI867024B (zh)	2019-08-14	2024-12-21	美商維泰克斯製藥公司	囊腫纖維化跨膜傳導調節蛋白之調節劑
CN114585628B (zh)	2019-08-14	2024-03-26	弗特克斯药品有限公司	囊性纤维化跨膜传导调节因子的调节剂
MX2022001828A (es)	2019-08-14	2022-06-08	Vertex Pharma	Formas cristalinas de moduladores del regulador de conductancia transmembrana de la fibrosis quistica (cftr).
TW202120517A (zh)	2019-08-14	2021-06-01	美商維泰克斯製藥公司	製備cftr調節劑之方法
BR112022011555A2 (pt) *	2019-12-20	2022-08-30	Intervet Int Bv	Composição farmacêutica de um composto pirazólico disperso em uma matriz polimérica
EP4164618A4 (en) *	2020-06-10	2024-06-19	Board of Regents, The University of Texas System	3D LASER SINTERING PROCESSES FOR ENHANCED DRUG DELIVERY
WO2022194399A1 (en)	2020-07-13	2022-09-22	Idorsia Pharmaceuticals Ltd	Macrocycles as cftr modulators
WO2022013360A1 (en)	2020-07-17	2022-01-20	Synthon B.V.	Pharmaceutical composition comprising ivacaftor
CR20230120A (es)	2020-08-07	2023-09-01	Vertex Pharma	Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
CA3188787A1 (en)	2020-08-13	2022-02-17	Vertex Pharmaceuticals Incorporated	Crystalline forms of cftr modulators
BR112023006470A2 (pt)	2020-10-07	2023-09-26	Vertex Pharma	Moduladores de regulador de condutância transmembrana de fibrose cística
WO2022076627A1 (en)	2020-10-07	2022-04-14	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
EP4225737A1 (en)	2020-10-07	2023-08-16	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
EP4225761A1 (en)	2020-10-07	2023-08-16	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
EP4225750A1 (en)	2020-10-07	2023-08-16	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
WO2022076621A1 (en)	2020-10-07	2022-04-14	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
KR20230104618A (ko)	2020-10-07	2023-07-10	버텍스 파마슈티칼스 인코포레이티드	낭성 섬유증 막관통 전도도 조절자의 조절제
WO2022076618A1 (en)	2020-10-07	2022-04-14	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
EP4225763A1 (en)	2020-10-07	2023-08-16	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
CR20230198A (es)	2020-10-07	2023-07-03	Vertex Pharma	Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
WO2022125826A1 (en)	2020-12-10	2022-06-16	Vertex Pharmaceuticals Incorporated	Methods of treatment for cystic fibrosis
EP4472635A1 (en)	2022-02-03	2024-12-11	Vertex Pharmaceuticals Incorporated	Methods of treatment for cystic fibrosis
KR20240155228A (ko)	2022-02-03	2024-10-28	버텍스 파마슈티칼스 인코포레이티드	(6a,12a)-17-아미노-12-메틸-6,15-비스(트리플루오로메틸)-13,19-디옥사-3,4,18-트리아자트리시클로[12.3.1.12,5]노나데카-1(18),2,4,14,16-펜타엔-6-올의 결정질 형태를 제조하는 방법
CN118974059A (zh)	2022-02-08	2024-11-15	弗特克斯药品有限公司	囊性纤维化跨膜传导调控因子的调节剂
IL315715A (en)	2022-04-06	2024-11-01	Vertex Pharma	Modulators of cystic fibrosis transmembrane conductance regulation
WO2023224924A1 (en)	2022-05-16	2023-11-23	Vertex Pharmaceuticals Incorporated	Solid forms of a macrocyclic compounds as cftr modulators and their preparation
WO2023224931A1 (en)	2022-05-16	2023-11-23	Vertex Pharmaceuticals Incorporated	Methods of treatment for cystic fibrosis
AU2023320558A1 (en)	2022-08-04	2025-01-23	Vertex Pharmaceuticals Incorporated	Compositions for the treatment of cftr-mediated diseases
EP4335434A1 (en)	2022-08-17	2024-03-13	Sanovel Ilac Sanayi Ve Ticaret A.S.	Pharmaceutical compositions comprising ivacaftor
TW202421102A (zh)	2022-09-15	2024-06-01	瑞士商愛杜西亞製藥有限公司	巨環cftr調節劑與cftr校正子及/或cftr增效劑之組合
TW202421636A (zh)	2022-09-15	2024-06-01	瑞士商愛杜西亞製藥有限公司	(3S,7S,10R,13R)-13-苄基-20-氟-7-異丁基-N-(2-(3-甲氧基-1,2,4-㗁二唑-5-基)乙基)-6,9-二甲基-1,5,8,11-四側氧基-10-(2,2,2-三氟乙基)-1,2,3,4,5,6,7,8,9,10,11,12,13,14-十四氫-[1]㗁[4,7,10,14]四氮雜環十七烷并[16,17-f]喹啉-3-甲醯胺的晶型
WO2024056798A1 (en)	2022-09-15	2024-03-21	Idorsia Pharmaceuticals Ltd	Macrocyclic cftr modulators

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2465597A1 (en)	2001-11-14	2003-06-12	Ben Zion Dolitzky	Amorphous and crystalline forms of losartan potassium and process for their preparation
CN101664411A (zh) *	2003-11-14	2010-03-10	味之素株式会社	苯丙氨酸衍生物的固体分散体或固体分散体医药制剂
JP2006206612A (ja) *	2004-05-27	2006-08-10	Ono Pharmaceut Co Ltd	固形製剤用組成物
LT1993360T (lt) *	2005-12-28	2017-06-12	Vertex Pharmaceuticals Incorporated	N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
MX2009006806A (es)	2006-12-22	2009-08-27	Vertex Pharma	Secado por rocio fluidizado.
EP2358721B1 (en) *	2008-10-23	2014-12-10	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator

2009
- 2009-08-13 EP EP20211291.8A patent/EP3842037A1/en active Pending
- 2009-08-13 SI SI200932107T patent/SI3345625T1/sl unknown
- 2009-08-13 HU HUE17204189A patent/HUE053357T2/hu unknown
- 2009-08-13 LT LTEP09789125.3T patent/LT2328618T/lt unknown
- 2009-08-13 BR BRPI0916877A patent/BRPI0916877A2/pt not_active Application Discontinuation
- 2009-08-13 EP EP09789125.3A patent/EP2328618B1/en active Active
- 2009-08-13 KR KR1020227014317A patent/KR20220057663A/ko not_active Ceased
- 2009-08-13 MX MX2018015847A patent/MX373230B/es unknown
- 2009-08-13 DK DK09789125.3T patent/DK2328618T3/en active
- 2009-08-13 DK DK17204189.9T patent/DK3345625T3/da active
- 2009-08-13 KR KR1020117005734A patent/KR20110042356A/ko active Search and Examination
- 2009-08-13 SI SI200931803T patent/SI2328618T1/en unknown
- 2009-08-13 JP JP2011522994A patent/JP5575768B2/ja active Active
- 2009-08-13 ES ES09789125.3T patent/ES2660143T3/es active Active
- 2009-08-13 PT PT172041899T patent/PT3345625T/pt unknown
- 2009-08-13 MX MX2014008855A patent/MX366161B/es unknown
- 2009-08-13 SM SM20210077T patent/SMT202100077T1/it unknown
- 2009-08-13 CA CA2733908A patent/CA2733908C/en active Active
- 2009-08-13 AU AU2009282419A patent/AU2009282419B2/en active Active
- 2009-08-13 KR KR1020177016117A patent/KR20170072950A/ko not_active Ceased
- 2009-08-13 KR KR1020197037948A patent/KR20190143497A/ko not_active Ceased
- 2009-08-13 NZ NZ591535A patent/NZ591535A/xx unknown
- 2009-08-13 RS RS20180161A patent/RS56894B1/sr unknown
- 2009-08-13 EP EP17204189.9A patent/EP3345625B1/en active Active
- 2009-08-13 PL PL17204189T patent/PL3345625T3/pl unknown
- 2009-08-13 WO PCT/US2009/004629 patent/WO2010019239A2/en active Application Filing
- 2009-08-13 HU HUE09789125A patent/HUE035931T2/hu unknown
- 2009-08-13 NO NO09789125A patent/NO2328618T3/no unknown
- 2009-08-13 RS RS20210129A patent/RS61408B1/sr unknown
- 2009-08-13 SM SM20180074T patent/SMT201800074T1/it unknown
- 2009-08-13 KR KR1020247015082A patent/KR20240066199A/ko active Pending
- 2009-08-13 EA EA201170330A patent/EA021706B1/ru unknown
- 2009-08-13 LT LTEP17204189.9T patent/LT3345625T/lt unknown
- 2009-08-13 MX MX2011001782A patent/MX2011001782A/es unknown
- 2009-08-13 ME MEP-2018-54A patent/ME03019B/me unknown
- 2009-08-13 PT PT97891253T patent/PT2328618T/pt unknown
- 2009-08-13 ES ES17204189T patent/ES2857152T3/es active Active
- 2009-08-13 PL PL09789125T patent/PL2328618T3/pl unknown
- 2009-08-13 CN CN2009801354496A patent/CN102231990B/zh active Active
2011
- 2011-02-10 ZA ZA2011/01097A patent/ZA201101097B/en unknown
- 2011-02-13 IL IL211203A patent/IL211203A/en active IP Right Grant
2012
- 2012-02-10 US US13/370,540 patent/US20120220625A1/en not_active Abandoned
- 2012-02-29 HK HK12102076.9A patent/HK1161140A1/xx unknown
2014
- 2014-03-12 JP JP2014048523A patent/JP2014111656A/ja not_active Withdrawn
2016
- 2016-08-16 AU AU2016216569A patent/AU2016216569B2/en active Active
2017
- 2017-05-21 IL IL252421A patent/IL252421B/en active IP Right Grant
2018
- 2018-02-22 HR HRP20180328TT patent/HRP20180328T1/hr unknown
- 2018-02-26 CY CY20181100229T patent/CY1119945T1/el unknown
- 2018-12-11 HK HK18115889.2A patent/HK1256805A1/zh unknown
2020
- 2020-07-05 IL IL275854A patent/IL275854A/en unknown
2021
- 2021-02-05 HR HRP20210208TT patent/HRP20210208T1/hr unknown
- 2021-02-22 CY CY20211100146T patent/CY1123901T1/el unknown

Also Published As

Publication number	Publication date
US20120220625A1 (en)	2012-08-30
CY1119945T1 (el)	2018-12-12
WO2010019239A3 (en)	2011-05-26
ES2857152T3 (es)	2021-09-28
CN102231990B (zh)	2013-09-25
IL275854A (en)	2020-08-31
AU2016216569A1 (en)	2016-09-01
HK1256805A1 (zh)	2019-10-04
AU2009282419B2 (en)	2016-05-19
KR20220057663A (ko)	2022-05-09
RS56894B1 (sr)	2018-04-30
IL252421A0 (en)	2017-07-31
EP3345625A1 (en)	2018-07-11
NO2328618T3 (hu)	2018-04-28
EA201170330A1 (ru)	2011-10-31
EP2328618B1 (en)	2017-11-29
ES2660143T3 (es)	2018-03-21
SI2328618T1 (en)	2018-04-30
AU2016216569B2 (en)	2018-01-25
CA2733908A1 (en)	2010-02-18
PL3345625T3 (pl)	2021-06-14
KR20240066199A (ko)	2024-05-14
ME03019B (me)	2018-10-20
SMT202100077T1 (it)	2021-05-07
JP5575768B2 (ja)	2014-08-20
CA2733908C (en)	2017-05-30
MX373230B (es)	2025-03-05
PT2328618T (pt)	2018-03-05
SI3345625T1 (sl)	2021-04-30
WO2010019239A2 (en)	2010-02-18
DK3345625T3 (da)	2021-02-01
EA021706B1 (ru)	2015-08-31
AU2009282419A1 (en)	2010-02-18
HK1161140A1 (hu)	2012-08-24
IL211203A0 (en)	2011-04-28
MX366161B (es)	2019-07-01
IL252421B (en)	2020-07-30
HRP20210208T1 (hr)	2021-03-19
KR20170072950A (ko)	2017-06-27
PT3345625T (pt)	2021-02-10
AU2009282419A2 (en)	2011-03-31
EP3345625B1 (en)	2020-12-09
KR20110042356A (ko)	2011-04-26
CY1123901T1 (el)	2022-05-27
KR20190143497A (ko)	2019-12-30
RS61408B1 (sr)	2021-03-31
CN102231990A (zh)	2011-11-02
SMT201800074T1 (it)	2018-05-02
LT3345625T (lt)	2021-02-10
HRP20180328T1 (hr)	2018-04-20
JP2014111656A (ja)	2014-06-19
BRPI0916877A2 (pt)	2016-02-10
MX2011001782A (es)	2012-02-08
JP2011530598A (ja)	2011-12-22
ZA201101097B (en)	2012-05-30
LT2328618T (lt)	2018-03-26
HUE053357T2 (hu)	2021-06-28
EP3842037A1 (en)	2021-06-30
NZ591535A (en)	2012-12-21
PL2328618T3 (pl)	2018-06-29
EP2328618A2 (en)	2011-06-08
IL211203A (en)	2017-06-29
DK2328618T3 (en)	2018-02-19

Publication	Publication Date	Title
HUE035931T2 (hu)	2018-06-28	N-[2,4-bis(1,1-dimetiletil)-5-hidroxipenil]-1,4-dihidro-4-oxokinolin-3-karboxamid gyógyszerészeti készítménye és annak alkalmazása
HUS2100018I1 (hu)	2021-06-28	Hatóanyagok légúti beadására alkalmas készítmények és ezekkel kapcsolatos eljárások
DK2464337T4 (da)	2024-07-22	Tabletformulering af N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinolin-3-carboxamid til anvendelse til behandling af cystisk fibrose
ZA201101477B (en)	2012-07-25	Co-crystals and pharmaceutical formulations comprising the same
DK3219705T3 (da)	2020-04-14	Farmaceutiske sammensætninger af den amorfe form af n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinolin-3-carboxamid
HUE061548T2 (hu)	2023-07-28	Komplementtel összefüggõ rendellenességek kezelésére szolgáló eljárások és készítmények
BRPI0807907A2 (pt)	2017-05-16	co-cristais e composições farmacêuticas compreendendo os mesmos.
BRPI0821871A2 (pt)	2015-06-16	Suspensão farmacêutica oral compreendendo paracetamol e ibuprofeno
BRPI0909750A2 (pt)	2015-10-06	dispositivo e cápsula para a preparação de uma bebida
BRPI0815385A2 (pt)	2009-02-12	Produtos medicinais farmaceuticamente revestidos melhorados, fabricação e uso dos mesmos
IL225198A (en)	2016-02-29	Aminotetrahydropyrenic Compounds, Pharmaceutical Preparations Containing Them and Their Use in the Treatment of Diabetes
IL206789A (en)	2015-11-30	A converted cyclic amide compound, a pharmaceutical preparation containing the compound and the use of a compound or pharmaceutical preparation in a pharmaceutical preparation
HUE037735T2 (hu)	2018-09-28	DesPro36exendin-4(1-39)-Lys6-NH2-t és metionint tartalmazó gyógyszerkészítmény
CR10406A (es)	2009-01-27	Nueva forma cristalina vi de la agomelatina, su procedimiento de preparacion y las composiciones farmaceuticas que la contienen
BRPI0912717A2 (pt)	2014-12-23	Composição farmacêutica, e, uso de 5-azacitidina
BRPI0816345A2 (pt)	2015-02-24	Formas sólidas de n-[2,4-bis-(1,1-dimetiletil)-5-hidroxifenil]-1,4-diidro-4-o xoquinolin-3-carboxamida
IL211400A0 (en)	2011-05-31	Substituted aminoindanes and analogs thereof, and the pharmaceutical use thereof
BRPI0921699A2 (pt)	2016-02-16	complexo antioxidante, composicoes cosmeticas e farmaceutica contendo o referido complexo e uso deste complexo
BRPI1009392A2 (pt)	2016-03-08	"formulação farmacêutica, e, uso de uma quantidade farmaceuticamente eficaz de uma formulação farmacêutica."
BRPI0816507A2 (pt)	2014-10-07	"produto comestível, processo para a preparação de uma cápsula revestida e uso de um produto comestível"
BRPI0917661A2 (pt)	2015-12-01	produto que contém macitentan, composição farmacêutica que o contém e uso de macitentan
EP2261221A4 (en)	2011-08-10	EPOTHILONE ANALOGUES, THEIR PHARMACEUTICAL COMPOSITIONS, THEIR USE AND PREPARATIONS
IL220586A (en)	2015-10-29	Carboxamide compound, a pharmaceutical composition containing it and its use
IL213177A0 (en)	2011-07-31	Crystal forms, methods of preparation, pharmaceutical compositions and uses of nicousamide
CL2013001164A1 (es)	2013-12-27	Composicion que contiene 2-metilpropanotioato de s-[2-([[1-(2-etilbutil)-ciclohexil]-carbonil]amino)fenilo] y croscarmelosa sodica; proceso de preparacion; tableta que la contiene; kit y uso en el tratamiento y prevencion de trastornos cardiovasculares.